Kumar S, Harrison S, Cavo M, et al. A phase 3 study of venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. 24th Congress of EHA, abstract LB2601.
Fysieke inactiviteit de grootste modificeerbare risicofactor in de geneeskunde
jan 2024 | Leukemie, Lymfoom, MDS, MM, MPN